- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic HER2-positive breast cancer after prior HER2-directed treatment
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 – May 2026 PBAC Meetings - (PDF 1.2MB)
- Public Summary Document (PSD) November 2025 – May 2026 PBAC Meetings - (Word 448.2KB)
Tucatinib – November 2025 – May 2026
Tucatinib: Tablet 50 mg Tablet 150mg; Tukysa® - November 2025
Last updated
5 November 2025